CJ CheilJedang sold 1.03 trillion won worth of Bibigo dumplings in 2020, with 65 percent generated from overseas.
This year’s sales were double that of the 506 billion won in 2017.
The US was the biggest market for Bibigo dumplings, recording sales of 420 billion won this year. China was second with 160 billion won, followed by Japan with 65 billion won.
Global sales first surpassed local sales in 2018.
According to CJ, it made efforts to get rid of the negative perceptions of frozen food to improve its image locally.
To boost sales in overseas markets, the company analyzed the different eating cultures and consumption patterns.
CJ also said it has invested to expand its production bases, from five in South Korea, the US, and China, to 15, including in Vietnam, Japan, and Germany.
The company's main target markets in Europe were the UK, France, and Germany, which are familiar with Asian cuisines. In the three countries, the company recorded a 61 percent average annual growth rate in the past three years.
According to a CJ CheilJedang official, their vision of people in the world having Korean food once a week has been realized.


SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme
OpenAI Tightens AI Safety Monitoring After Security Incidents
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push
Shein Targets $26B-$27B Valuation for Hong Kong IPO
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3
REPAY Stock Rises After Visa Platform Connect Collaboration
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows
Coty Revenue Beats Estimates as Beauty Demand Holds Firm
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 



